A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

Overview of attention for article published in Breast Cancer Research and Treatment, July 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

So far, Altmetric has seen 7 patents that reference this research output.

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 3 additional patents.